Related Experiment Video

Updated: Jun 1, 2026

Flow Cytometric Detection of Newly-formed Breast Cancer Stem Cell-like Cells After Apoptosis Reversal
11:21

Flow Cytometric Detection of Newly-formed Breast Cancer Stem Cell-like Cells After Apoptosis Reversal

Published on: January 26, 2019

New cancer strategy - apoptosis based therapy by growth-factors (review)

Y Murayama, Y Mishima

    Oncology Reports
    |May 21, 2011
    PubMed

    Insights

    Epidermal growth factor (EGF) and transforming growth factor-beta1 (TGF-beta1) influence cell growth. High EGF concentrations induce apoptosis in breast and esophageal cancers, highlighting their potential in apoptosis-based cancer therapy.

    Area of Science:

    • Cell biology
    • Molecular oncology
    • Cancer research

    Background:

    • Epidermal growth factor (EGF) and transforming growth factor-beta1 (TGF-beta1) exhibit dual roles in regulating cell proliferation.
    • Understanding their signal transduction pathways is crucial for cancer treatment strategies.

    Purpose of the Study:

    • To review and discuss the signal transduction of EGF and TGF-beta1.
    • To highlight the role of these growth factors in cell cycle progression and apoptosis.
    • To explore the potential of apoptosis-based cancer therapy.

    Main Methods:

    • Literature review of signal transduction pathways.
    • Analysis of in vivo studies on EGF and TGF-beta1 effects on cancer cells.
    • Emphasis on the role of p53 and RB genes.

    Main Results:

    • EGF and TGF-beta1 signaling impacts cell cycle and apoptosis.
    • High concentrations of EGF induce apoptosis in breast and esophageal cancer models.
    • p53 and RB genes are critical regulators of cell cycle and apoptosis.

    Conclusions:

    • EGF and TGF-beta1 are key regulators of cell fate.
    • Targeting these pathways, particularly through induced apoptosis, offers a promising cancer therapy strategy.
    • The p53 and RB tumor suppressor genes play a central role in mediating these effects.

    More Related Videos

    Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

    Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

    Published on: May 30, 2012

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    The Intrinsic Apoptotic Pathway01:31

    The Intrinsic Apoptotic Pathway

    Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...